Cardiovascular Toxicities of Androgen Deprivation Therapy [PDF]
Prostate cancer is the second leading cause of cancer death in men, and cardiovascular disease is the number one cause of death in patients with prostate cancer. Androgen deprivation therapy, the cornerstone of prostate cancer treatment, has been associated with adverse cardiovascular events.
Azariyas A. Challa +12 more
openaire +2 more sources
OBJECTIVE: : At the time of diagnosis, approximately 16.5% of prostate cancer patients are metastatic. The main framework of metastatic prostate cancer treatment is androgen deprivation therapy, which is performed surgically or medically. The aim of this
Kisa, Erdem +22 more
core +1 more source
Amplification of the androgen receptor may not explain the development of androgen-independent prostate cancer [PDF]
Objective To examine the role of androgen receptor (AR) gene amplification and aneusomy of the X chromosome in the development of antiandrogen-resistant prostate cancer.
Watters, A.D. +11 more
core +1 more source
The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: modifications to the androgen receptor [PDF]
Prostate cancer is the second most common male malignancy in the western world an increasing incidence in an ageing population. Treatment of advanced prostate cancer relies on androgen deprivation.
Edwards, J., Bartlett, J.M.S.
core +1 more source
Long-term cardiovascular burden in prostate cancer patients receiving androgen deprivation therapy [PDF]
Androgen deprivation therapy (ADT), which pharmacologically or surgically suppresses androgen activity, is a key treatment for prostate cancer (PCa).1 However, it is associated with increased cardiovascular risks, including elevated risks of ...
Tse, G.
core
Outcomes of patients older than 75 years with non-metastatic prostate cancer
Objective: Prostate cancer in elderly patients was formerly treated with androgen deprivation therapy. Since the latter of the 1990s new technologies were introduced into treatments, then strategies have varied.
Yoshiyasu Amiya +8 more
doaj +1 more source
Bad expression influences time to androgen escape in prostate cancer [PDF]
<b>OBJECTIVE</b>: To assess the role of selected downstream Bcl-2 family members (Bad, Bax, Bcl-2 and Bcl-xL) in the development of androgen-independent prostate cancer (AIPC), as androgen-deprivation therapy is the treatment of choice in ...
Teo, K. +4 more
core +1 more source
Androgen deprivation therapy is a common treatment for prostate cancer. However, this therapy is associated with various adverse effects, such as increased body fat and decreased bone mineral density. Exercise may be useful for ameliorating these adverse
Wenjuan Shao +3 more
doaj +2 more sources
NON-GENOMIC ANDROGEN ACTION REGULATES PROLIFERATIVE/MIGRATORY SIGNALLING IN STROMAL CELLS.
Prostate cancer is the major cause of cancer-related death among the male population of Western society, and androgen deprivation therapy represents the first line in prostate cancer treatment. However, although androgen receptor expression is maintained
Marzia eDi Donato +9 more
doaj +1 more source
Androgen receptor and MYC equilibration centralizes on developmental super-enhancer
Androgen receptor in prostate cancer (PCa) transcriptionally represses multiple genes including MYC. Here, the authors suggest that increased MYC in response to androgen deprivation contributes to castration-resistant PCa, while decreased MYC may ...
Haiyang Guo +15 more
doaj +1 more source

